The role of vaccination in preventing pneumococcal disease in adults - PubMed (original) (raw)

Review

The role of vaccination in preventing pneumococcal disease in adults

S Aliberti et al. Clin Microbiol Infect. 2014 May.

Abstract

Pneumococcal infections, including pneumonia and invasive disease, are major sources of morbidity and mortality worldwide. Prevention of the first acquisition of Streptococcus pneumoniae through the use of vaccines represents an effective method to reduce the burden of the disease in both children and adults. Two vaccines are currently available in adults: a pneumococcal polysaccharide vaccine (PPV23) that includes 23 purified capsular polysaccharide antigens and a pneumococcal protein-conjugate vaccine (PCV13) that includes capsular polysaccharide antigens covalently linked to a non-toxic protein. The PPV23 induces a humoral immune response and since it has been licensed has been the subject of debates and controversies. Numerous studies and meta-analyses have shown that PPV23 protects against invasive pneumococcal disease, although there are conflicting data regarding its efficacy for the prevention of pneumonia. Vaccination with PCV13 stimulates good antibody responses as well as mucosal immunity and suppresses colonization. A conjugate vaccine can be expected to have benefits over a polysaccharide vaccine because of the characteristics of a T-cell-dependent response in terms of affinity, maturation of antibodies with repeated exposure, induction of immunological memory and long-lasting immunity. PCV13 has demonstrated all of these characteristics in children and fundamental differences in adults are not expected. The efficacy in adults is currently being investigated and results will be available soon.

Keywords: Invasive pneumococcal disease; Streptococcus pneumoniae; pneumococcal; pneumonia; vaccination; vaccine.

© 2014 The Authors Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases.

PubMed Disclaimer

Conflict of interest statement

Transparency Declaration

All the authors declare that they have no conflicts of interest.

Figures

FIG. 1

FIG. 1

PCV13 and PPV23: suggestions for pneumococcal vaccine use in immunocompetent patients. PCV13, pneumococcal 13-valent conjugate vaccine; PPV23, pneumococcal polysaccharide 23-valent vaccine.

FIG. 2

FIG. 2

PCV13 and PPV23: suggestion for pneumococcal vaccine use in immunocompromised patients. PCV13, pneumococcal 13-valent conjugate vaccine; PPV23, pneumococcal polysaccharide 23-valent vaccine; HIV, human immunodeficiency virus.

Similar articles

Cited by

References

    1. Varon E, Mainardi JL, Gutmann L. Streptococcus pneumoniae: still a major pathogen. Clin Microbiol Infect. 2010;16:401. - PubMed
    1. Center for Disease Control Prevention. Defining the public health impact of the drug resistant Streptococcus pneumoniae: report of a working group. MMWR Morb Mortal Wkly Rep. 1996;45:1–21. - PubMed
    1. Lexau CA, Lynfield R, Danila R, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA. 2005;294:2043–2051. - PubMed
    1. Siemieniuk R, Gregson DB, Gill MJ. The persisting burden of invasive pneumococcal disease in HIV patients: an observational cohort study. BMC Infect Dis. 2011;11:314. - PMC - PubMed
    1. Blasi F, Mantero M, Santus P, Tarsia P. Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect. 2012;18(suppl 5):7–14. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources